- Home
- PRQR vs NAN Comparison
PRQR vs NAN Comparison
Compare PRQR & NAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRQR
- NAN
- Stock Information
- Founded
- PRQR 2012
- NAN 1999
- Country
- PRQR Netherlands
- NAN United States
- Employees
- PRQR N/A
- NAN N/A
- Industry
- PRQR Biotechnology: Pharmaceutical Preparations
- NAN Investment Managers
- Sector
- PRQR Health Care
- NAN Finance
- Exchange
- PRQR Nasdaq
- NAN Nasdaq
- Market Cap
- PRQR 309.5M
- NAN 352.5M
- IPO Year
- PRQR 2014
- NAN N/A
- Fundamental
- Price
- PRQR $1.43
- NAN $11.23
- Analyst Decision
- PRQR Strong Buy
- NAN
- Analyst Count
- PRQR 5
- NAN 0
- Target Price
- PRQR $9.80
- NAN N/A
- AVG Volume (30 Days)
- PRQR 583.9K
- NAN 74.6K
- Earning Date
- PRQR 05-08-2025
- NAN 01-01-0001
- Dividend Yield
- PRQR N/A
- NAN 4.37%
- EPS Growth
- PRQR N/A
- NAN N/A
- EPS
- PRQR N/A
- NAN N/A
- Revenue
- PRQR $20,235,014.00
- NAN N/A
- Revenue This Year
- PRQR $6.44
- NAN N/A
- Revenue Next Year
- PRQR N/A
- NAN N/A
- P/E Ratio
- PRQR N/A
- NAN N/A
- Revenue Growth
- PRQR 196.41
- NAN N/A
- 52 Week Low
- PRQR $1.07
- NAN $9.11
- 52 Week High
- PRQR $4.62
- NAN $11.34
- Technical
- Relative Strength Index (RSI)
- PRQR 50.71
- NAN 49.25
- Support Level
- PRQR $1.10
- NAN $10.86
- Resistance Level
- PRQR $1.26
- NAN $11.26
- Average True Range (ATR)
- PRQR 0.13
- NAN 0.23
- MACD
- PRQR 0.07
- NAN 0.01
- Stochastic Oscillator
- PRQR 73.47
- NAN 75.35
About PRQR ProQR Therapeutics N.V.
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.
About NAN Nuveen New York Quality Municipal Income Fund
Nuveen New York Quality Municipal Income Fund is a diversified closed-end management investment company. Its investment objective is to provide current income exempt from regular federal, New York State and New York City income tax and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.